How would you treat oligometastatic NSCLC (brain and bone) with Non-V600E BRAF mutations?
SRS done to the single brain met, PD-L1 5%, BRAF G469A mutation
Community PollStarted
How would you treat frontline metastatic NSCLC with BRAF non-V600E mutations with PD-L1 <50%?
131 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet Member
Medical Oncology · University of Oklahoma Health Sciences Center
Answered on
I would treat with chemo-pembro. Down the road, MEK inhibitors is a choice.
Join for free or sign in to see the full answer